Optimizing chemotherapy dose and schedule by Norton-Simon mathematical modeling

Breast Disease

Volumn 31, Issue 1, 2010, Pages 7-18

  Traina, Tiffany A ^a   Dugan, Ute ^b   Higgins, Brian ^b   Kolinsky, Kenneth ^b   Theodoulou, Maria ^a   Hudis, Clifford A ^a   Norton, Larry ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b HOFFMANN LA ROCHE INC   (United States)

Author keywords

capecitabine; chemotherapy schedule; mathematical model; Norton Simon; Xeloda

Indexed keywords

CAPECITABINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHEMICAL REACTION KINETICS; CONTROLLED STUDY; DRUG APPROVAL; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG RESEARCH; DRUG SAFETY; MATHEMATICAL COMPUTING; MATHEMATICAL MODEL; MOUSE; NONHUMAN; OPTIMAL DRUG DOSE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROCESS OPTIMIZATION; SURVIVAL RATE; TUMOR VOLUME; XENOGRAFT;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; BREAST NEOPLASMS; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; MICE; MODELS, THEORETICAL; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 78751477722     PISSN: 08886008     EISSN: None     Source Type: Journal    
DOI: 10.3233/BD-2009-0290     Document Type: Article

References (48)

1. E. Chu, Pharmacology of Cancer Chemotherapy: Drug Development, in: Cancer Principles and Practice of Oncology, H.a.R. DeVita, Editor, Lippincott Williams andWilkins: New York, 2005, pp. 307-317.
2. C. Takimoto, Pharmacology of Cancer Chemotherapy: Pharmacokinetics, in: Cancer Principles and Practice of Oncology, H.a.R. DeVita, Editor, Lippincott Williams & Wilkins: New York, 2005, pp. 317-327.
3. B. Fisher et al., Increased intensification and total dose of cyclophosphamide in a doxorubicincyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B22, J Clin Oncol 15(5) (1997), 1858-1869.
4. I.C. Henderson et al., Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with nodepositive primary breast cancer, J Clin Oncol 21(6) (2003), 976-983.
5. E.P.Winer et al., Failure of higherdose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342, J Clin Oncol 22(11) (2004), 2061-2068.
6. W.P. Peters et al., Highdose chemotherapy and peripheral blood progenitor cell transplantation in the treatment of breast cancer, Oncologist 5(1) (2000), 1-13.
7. L. Norton et al., Predicting the course of Gompertzian growth, Nature 264 (1976), 542-545.
8. L. Norton and R. Simon, The growth curve of an experimental solid tumor following radiotherapy, Journal of the National Cancer Institue 58 (1977), 1735-1741.
9. L. Norton and R. Simon, Tumor size, sensitivity to therapy, and design of treatment schedules, Cancer Treatment Reports 61(7) (1977), 1307-1315.
10. L. Norton and R. Simon, The NortonSimon hypothesis revisited, Cancer Treatment Reports 70 (1986), 163-169.
11. J. Speer et al., A stochastic numerical model of breast cancer that simulates clinical data, Cancer Res 44 (1984), 4124.
12. J.A. Spratt et al., Mammographic assessment of human breast cancer growth and duration, Cancer 71(6) (1993), 2020-2026.
13. J.A. Spratt et al., Decelerating growth and human breast cancer, Cancer 71(6) (1993), 2013-2019.
14. S. Koscielny, M. Tubiana and A.J. Valleron, A simulation model of the natural history of human breast cancer, Br J Cancer 52(4) (1985), 515-524.
15. L. Norton, A Gompertzian model of human breast cancer growth, Cancer Research 48 (1988), 7067-7071.
16. L. Norton, Evolving concepts in the systemic drug therapy of breast cancer, Semin Oncol 24(4 Suppl 10) (1997), S103S1010.
17. L. Norton, Theoretical concepts and the emerging role of taxanes in adjuvant therapy, Oncologist 6 Suppl 3 (2001), 30-35.
18. M.J. PiccartGebhart, Mathematics and oncology: amatch for life? J Clin Oncol 21(8) (2003), 1425-1428.
19. L. Norton, Conceptual and practical implications of breast tissue geometry: toward a more effective, less toxic therapy, Oncologist 10(6) (2005), 370-381.
20. G. Bonadonna, M. Zambetti and P. Valagussa, Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Tenyear results, Jama 273(7) (1995), 542-547.
21. H.E. Skipper, Kinetics of mammary tumor cell growth and implications for therapy, Cancer 28(6) (1971), 1479-1499.
22. H. Skipper, Analysis of multiarmed trials in which animals bearing different burdens of L1210 leukemia cells were treated with 2, 3, and 4 drug combinations delivered in different ways with varying dose intensities of each drug and varying average dose intensities, Southern Research Institute Booklet 7 420 (1986), 87-92.
23. M.L. Citron et al., Randomized trial of dosedense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of nodepositive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741, J Clin Oncol 21(8) (2003), 1431-1439.
24. M. Citron et al., Dosedense (DD) AC followed by paclitaxel is associated with moderate, frequent anemia compared to sequential (S) and/or less DD Treatment: Update by CALGB on Breast Cancer Intergroup Trial C9741 with ECOG, SWOG, & NCCTG. in American Society of Clinical Oncology, 2005.
25. M.Miwa et al., Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue, Eur J Cancer 34(8) (1998), 1274-1281.
26. J.L. Blum et al., Multicenter, Phase II study of capecitabine in taxanepretreated metastatic breast carcinoma patients, Cancer 92(7) (2001), 1759-1768.
27. J.L. Blum et al., Multicenter phase II study of capecitabine in paclitaxelrefractory metastatic breast cancer, J Clin Oncol 17(2) (1999), 485-493.
28. P. Reichardt et al., Multicenter phase II study of oral capecitabine (Xeloda ) in patients with metastatic breast cancer relapsing after treatment with a taxanecontaining therapy, Ann Oncol 14(8) (2003), 1227-1233.
29. J.A. O'Shaughnessy et al., Randomized, openlabel, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5fluorouracil) as firstline therapy for advanced/metastatic breast cancer, Ann Oncol 12(9) (2001), 1247-1254.
30. Food and Drug Administration, FDA approves Xeloda for breast cancer. 1998, U.S. Department of Health and Human Services.
31. Food andDrugAdministration, FDA Approves Xeloda inCombination with Taxotere for Advanced Breast Cancer 2001, US Dept of Health and Human Services.
32. E.A. Perez et al., Efficacy and safety of ixabepilone (BMS247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine, J Clin Oncol 25(23) (2007), 3407-3414.
33. C.E. Geyer et al., Lapatinib plus capecitabine for HER2positive advanced breast cancer, N Engl JMed 355(26) (2006), 2733-2743.
34. D.R. Budman et al., Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine, J Clin Oncol 16(5) (1998), 1795-1802.
35. M. Mackean et al., Phase I and pharmacologic study of intermittent twicedaily oral therapy with capecitabine in patients with advanced and/or metastatic cancer, J Clin Oncol 16(9) (1998), 2977-2985.
36. E. Van Cutsem et al., Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study, J Clin Oncol 18(6) (2000), 1337-1345.
37. K.D. Miller et al., Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer, J Clin Oncol 23(4) (2005), 792-799.
38. B.T. Hennessy et al., Lower dose capecitabine has a more favorable therapeutic index in metastatic breast cancer: retrospective analysis of patients treated atM. D. Anderson Cancer Center and a review of capecitabine toxicity in the literature, Ann Oncol 16(8) (2005), 1289-1296.
39. M. Yanagisawa, K. FOuchi and Y. Tanaka, Optimal dosing schedule of capecitabine administration in human mammary tumor xenograft models, Proc AACR (2004), 225.
40. L.Norton et al., OptimizingChemotherapeuticDoseSchedule (CDS) by NortonSimon Modeling: Capecitabine (Xeloda ). Annual Meeting of American Association for Cancer Research. 2005. Anaheim, CA.
41. B. Higgins et al., Antitumor activity of capecitabine and bevacizumab combination in a human estrogen receptornegative breast adenocarcinoma xenograft model, Anticancer Res 27(4B) (2007), 2279-2287.
42. T. Traina et al., In Vivo Activity of a Novel Regimen of Capecitabine in a Breast Cancer XenograftModel Breast Cancer Research and Treatment, 2006. 2006 San Antonio Breast Cancer Symposium Proceedings: p. Abstract 6071.
43. W. Scheithauer et al., Intermittent weekly highdose capecitabine in combination with oxaliplatin: a phase I/II study in firstline treatment of patientswith advanced colorectal cancer, Ann Oncol 13(10) (2002), 1583-1589.
44. W. Scheithauer et al., Biweekly highdose gemcitabine alone or in combination with capecitabine in patients withmetastatic pancreatic adenocarcinoma: a randomized phase II trial, Ann Oncol 14(1) (2003), 97-104.
45. T.A. Traina et al., Phase I study of a novel capecitabine schedule based on theNortonSimonmathematicalmodel in patients with metastatic breast cancer, J Clin Oncol 26(11) (2008), 1797-1802.
46. T. Traina et al., Safety of a novel capecitabine dosing schedule when combined with lapatinib in patients with HER2positive metastatic breast cancer refractory to trastuzumab, Journal of Clinical Oncology 27(18S) (2009).
47. T.A. Traina et al., A novel capecitabine dosing schedule combined with bevacizumab is safe and active in patients with metastatic breast cancer: A phase II study, J Clin Oncol 26 (20 May 2008, suppl; abstr 1101).
48. J. Lewis et al., Evaluation of indibulin, a novel tubulin targetingagent, in combination with capecitabine, with mathematically optimized dose scheduling, J Clin Oncol (Meeting Abstracts) 27 (2009), (15s (suppl; abstr 2538)).